› Forums › General Melanoma Community › Lag-3 + Nivo vs Nivo clinical trial data released from ASCO
- This topic has 3 replies, 4 voices, and was last updated 3 years, 9 months ago by
MelMel.
- Post
-
- June 6, 2021 at 12:50 pm
Results are very strong for a possible new front line treatment option for stage 4 patients. https://dailynews.ascopubs.org/do/10.1200/ADN.21.200597/full/?fbclid=IwAR2GUYBzFrZuEM2RzZatI5-kKhoJMMTDoNivKX8VWwhodkyU32SbAp2x3J0
Viewing 2 reply threads
- Replies
-
-
- June 7, 2021 at 9:51 pm
<p style=”text-align: left;”>I know that all melanoma development is local, in the sense that if a new treatment doesn’t impact a great number of people, but you’re a complete responder to it, that’s the biggest news of all in your universe. That said, is this the biggest thing coming down down the pipe in terms of greatest potential impact on the most people? Seems like pd1 and ctla4 cp blockers have been the biggest to date, so introducing a third on the level (is it on that level?) would be huge. Anything bigger in the works?</p> -
- June 8, 2021 at 9:26 pm
Thank you Ed.I have a question to ask re PET scans. I have general knowledge but that is not good enough so here goes.
Mediastinal blood pool SUV avg is 2.2. Hepatic parenchyma SUV avg is 2.8.
Stable non-FDG avid 0.5 cm right middle lobe nodule.
Can you shed some light or point me in the right direction please? Thank you in advance.
Melanie
Viewing 2 reply threads
- You must be logged in to reply to this topic.